A new publication co-authored by Per Bäckman, Senior Adviser at Emmace, marks the fourth paper in a series on the Inhalation Biopharmaceutics Classification System (iBCS). Published in Molecular Pharmaceutics, the study explores how iBCS can be applied throughout drug discovery, development, and regulatory evaluation for orally inhaled drug products (OIDPs). By classifying inhaled drugs based on dose, solubility, and permeability, iBCS serves as a valuable tool for formulation scientists to predict drug performance and mitigate development risks.

Per Bäckman and fellow researchers highlight the need for standardized experimental methods to enhance iBCS, making it more applicable in both new drug formulation and generic product development. The paper also discusses how iBCS could eventually streamline bioequivalence assessments, potentially reducing the need for costly clinical studies.

This research contributes to a growing body of work aimed at improving inhaled drug development, leading to safer and more effective therapies.

Read the full article.